Pharmalink (Sweden)
Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Pharmalink now aims to further Nefecon through Phase 3 to registration. In addition, the Company has identified other potential uses of Nefecon and will investigate opportunities for development in these other niche indications as a means to maximize value and to provide new medications for patients with unmet medical needs. Pharmalink is focused on the development and commercial
Basic Information
- Category: business
- Website: http://www.pharmalink.se/
Documented Facts
- Inception (Wikidata): 1991 (Source 2: Wikidata Q30269252, revision 2474422485)
- Country (Wikidata; date unspecified): Sweden (Source 2: Wikidata Q30269252, revision 2474422485; Source 3: Wikidata label: Q34, revision 2547805093)
- Official website (Wikidata; date unspecified): http://www.pharmalink.se/ (Source 2: Wikidata Q30269252, revision 2474422485)
Evidence and Sources
- Pharmalink (Sweden) — Official Website (official)
- Wikidata Q30269252, revision 2474422485 (knowledge-base)
- Wikidata label: Q34, revision 2547805093 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Pharmalink (Sweden).
- Canonical profile: https://brandsource.ai/brands/pharmalink-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/pharmalink-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/pharmalink-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Pharmalink now aims to further Nefecon through Phase 3 to registration. In addition, the Company has identified other potential uses of Nefecon and will investigate opportunities for development in these other niche indications as a means to maximize value and to provide new medications for patients with unmet medical needs. Pharmalink is focused on the development and commercial
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.